Michael Tankelevich
Overview
Explore the profile of Michael Tankelevich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
1182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bloemen H, Livanos A, Martins A, Dean R, Bravo A, Bourgonje A, et al.
Clin Gastroenterol Hepatol
. 2024 Nov;
PMID: 39490950
Background & Aims: Anti-integrin αvβ6 autoantibodies (anti-αvβ6) are found in more than 50% of individuals with ulcerative colitis (UC). We aimed to determine the prevalence of anti-αvβ6 in patients with...
2.
Cossarini F, Shang J, Krek A, Al-Taie Z, Hou R, Canales-Herrerias P, et al.
Sci Immunol
. 2024 Oct;
9(100):eado0090.
PMID: 39454027
Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high-resolution mapping of human B cells and PCs sampled...
3.
Cossarini F, Shang J, Krek A, Al-Taie Z, Hou R, Canales-Herrerias P, et al.
bioRxiv
. 2024 Jun;
PMID: 38826293
One Sentence Summary: Intestinal germinal center B cell reduction in HIV-1 infection linked to reduced IgA plasma cells and systemic inflammation.
4.
Canales-Herrerias P, Uzzan M, Seki A, Czepielewski R, Verstockt B, Livanos A, et al.
Sci Immunol
. 2024 Apr;
9(94):eadg7549.
PMID: 38640252
Vedolizumab (VDZ) is a first-line treatment in ulcerative colitis (UC) that targets the α4β7- mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) axis. To determine the mechanisms of action of...
5.
Jha D, Al-Taie Z, Krek A, Toghi Eshghi S, Fantou A, Laurent T, et al.
bioRxiv
. 2023 Jun;
PMID: 37333091
Ulcerative colitis (UC) is an idiopathic chronic inflammatory disease of the colon with sharply rising global prevalence. Dysfunctional epithelial compartment (EC) dynamics are implicated in UC pathogenesis although EC-specific studies...
6.
Canales-Herrerias P, Garcia-Carmona Y, Shang J, Meringer H, Yee D, Radigan L, et al.
J Clin Invest
. 2023 May;
133(12).
PMID: 37129981
No abstract available.
7.
Canales-Herrerias P, Uzzan M, Seki A, Czepielewski R, Verstockt B, Livanos A, et al.
bioRxiv
. 2023 Jan;
PMID: 36711839
Targeting the α4β7-MAdCAM-1 axis with vedolizumab (VDZ) is a front-line therapeutic paradigm in ulcerative colitis (UC). However, mechanism(s) of action (MOA) of VDZ remain relatively undefined. Here, we examined three...
8.
Britton G, Chen-Liaw A, Cossarini F, Livanos A, Spindler M, Plitt T, et al.
Sci Rep
. 2021 Jun;
11(1):13308.
PMID: 34172783
Gastrointestinal symptoms are common in COVID-19 patients but the nature of the gut immune response to SARS-CoV-2 remains poorly characterized, partly due to the difficulty of obtaining biopsy specimens from...
9.
Livanos A, Jha D, Cossarini F, Gonzalez-Reiche A, Tokuyama M, Aydillo T, et al.
Gastroenterology
. 2021 Mar;
160(7):2435-2450.e34.
PMID: 33676971
Background & Aims: Given that gastrointestinal (GI) symptoms are a prominent extrapulmonary manifestation of COVID-19, we investigated intestinal infection with SARS-CoV-2, its effect on pathogenesis, and clinical significance. Methods: Human...
10.
Gaebler C, Wang Z, Lorenzi J, Muecksch F, Finkin S, Tokuyama M, et al.
Nature
. 2021 Jan;
591(7851):639-644.
PMID: 33461210
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected 78 million individuals and is responsible for over 1.7 million deaths to date. Infection is associated with the development of variable...